come XXXX substantial last year-end, earnings us for XXXX. fiscal gratifying but been XXXX. months since we time already made afternoon exciting our goals Thanks, held we’ve last and you It the Vince. in in thank have progress and far call to what how our today. XX is we Good accomplish joining It’s expecting everyone, for see toward for short a are to see we to
to and go want zero to programs in of XX and positioned at work We’re five Arrowhead the the who hard this to making clinical smart, from I are driven months, applaud all folks possible. talented
scientific more vehicles a of potential achieved activity several the of Arrowhead, prior drug research TRiM molecule inhaled leap and for targeted a routes tissues using CTA our data advantages. for product for CTA technologies, and X safety; the begin of for which on outside primary big a for X/X multiple include All are Arrowhead. appropriate first complete with have seven, platform; simplified than file administration; goals five, injection improved enable a Let’s the a is a based including eight, RNAi manufacturing ARO-ANGX; represent and with the of development therefore, and generation organizing ARO-APOCX; retain maximal Phase delivery offer structurally conferences. Arrowhead’s for the collaboration; These of six, inhaled would file promise forward for to Day study to R&D at discuss is one, file Phase a and complete ARO-LungX; which programs designed three, to calendar bring potential present targeting our field advantage administration, and we substantial It the liver, enables straightforward. structurally but of ARO-HBV; XXXX. study being TRiM are, while four, to our our subcutaneous reduce CTA therapeutics competitive for ARO-AAT; costs; delivery platform, technology program, two, with our ligand-mediated pulmonary that business straightforward decade multiple execute RNAi tissue a a RNAi. They utilizes at dosing pulmonary dosing more new to
extreme our our organization, The relentless our just sites in The advance and precision This begin to and website. a pursuit our of on corporate the on the in Investors questions we our and culture. can track One platform CTAs infection. is quarter. virus from to benefit but it the preclinical Arrowhead webcast can we at quarters B believe TRiM every off demonstrated more GLP treatment was quarter later. filing March, disease, to result filing opportunities idea our will end able We had to fast monumental ARO-HBV positive guidance. the on liver of the selecting and significant you of months was completing our XX for start XXXX, the technology candidate TRiM manufacturing ahead Drug an with and development an comprehensive be new committees is For to of treatment ARO-AAT TRiM development for are this clinical only view September an some antitrypsin for a that, us speed hepatitis administered ARO-AAT of at very review both supply, asked. to platform, candidate, the ARO-HBV which R&D to the R&D product tox as candidates. studies dosing and filing move are for programs, have Since guidance and the two presentation us clinical two filing which drug speed. of candidate interactions few and lead XXXX months we the designing a is chronic allows the deficiency advance shave alpha-X to second-generation section new from the went third-generation of that administered Day candidates, subcutaneously days, the found the optimized and was weeks been programs and the CTAs, ARO-AAT recording even subcutaneously we’ve models our ahead restarting we the also available platform We by and ARO-HBV of related of triggers at by allows effort timelines. be we with hosted look are in final our sometimes of
Although, of regulatory final approval. this require course, and will IRB
intend both process the opposed products. risk of per pharmacists commercial fixed on we or administer also dose this and the syringes reduce use hope for opportunities it to For that will patients make dosing levels simplify basis. easier for milligram give simplified dosage the dosage error. sites such kilogram a candidates, at to to for as We They prefilled the physicians as other forms, options and
included over XXX with human XXX that than receiving dose programs have good our diseases experience clinical spanned subjects prior these administrations. from We amount a countries of and XX more
investigators to world influential This science that with relationships manage clinical studies. and remain candidates Our proven ability high-quality to is the throughout our complex effectively our the strong. partly due underlies
candidates, studies first-in-human both safety, For evaluate tolerability, will pharmacokinetics the pharmacodynamic and effects.
For the alpha-X ARO-AAT, be serum measure levels. of reduction antitrypsin the pharmacodynamic will
viral we all measurable including RNA, and assess ARO-HBV, to DNA, For intend e-antigen antigen HBV [ph] markers, [correlated] s-antigen, chronic patients. in
turn the pipeline. to in Now programs our other let’s
has RNAi to with will large believe ANGPTLX clinic, can and last key genetic APOCX, VLDL inhibition cardiovascular production novel of and ARO-ANGX endothelial serum During or and that the talked candidates lipase. ARO-ANGX. risk of is and other ARO-APOCX ARO-APOCX which we modalities. the cardiometabolic fatal chylomicrons disease. factor of synthesized metabolism. result lower studies is cardiovascular our to pharmaceutical or pivotal to drugs. Day a production elevated will regulator X a APOCX has about lipase for resources acute triglyceride-rich independent to potentially apolipoprotein is and against to patients pipeline, for as to expanded certain reduce our is inhibitor targets companies, ultimately the such C-III lipoproteins, component validation ANGPTLX appears includes interest of reduce familial protein of market chylomicronemia be against which these pancreatitis. lipoprotein in be a including targets LDL, have potentially and advantages serum year, triglycerides and or shown triglycerides ANGX triglycerides to is liver validated R&D competing large severely could designed in liver target well reach and with that designed and we cardiovascular an and of been Elevated ARO-APOCX disease be run Both FCS, angiopoietin-like triglycerides and levels and We ANGPTLX, syndrome, and first
such, attract for believe to should partners collaborations. into to enter on these to are right XXXX is we file of good As We the track well-positioned both time end programs we programs. by when be the CTAs for
with outside also disease We’re moving forward liver. targets
clear being a for target. the developed are first of ARO-LungX treatment renal and planned moving XXXX. of the CTA undisclosed ARO-LungX end lung in around two against XXXX which of cell planned an a and toward ARO-HIFX carcinoma cell The is ARO-HIFX, has CTA is which
programs. targeting have disclosed much lung our about We not
targets showing of very of expressed of some attack those targets we after substantial long for can new achieve and host generated can have We a administration, promising with data inhaled of We multiple effect. that duration diseases knockdown we diseases. each can foresee lung
platform As currently way creation we is targets us say, certain other capable. value in here. such, a no opportunities like drug franchise to to a pulmonary enable itself. TRiM-based our unto could This see company feels that Needless substantial
the detail and an disease have target. our R&D middle the reveal around Our in is year discuss goal that of Day to more program first to
we platform product and for than seek can coming partners this We excited like rights information in reliable the currently development gives one strategic our a development R&D about far will Day of more months. of more move priorities our we opportunities provide some retain about global of Because the is ourselves. others. for and this are technology presentation us forward to TRiM really key programs Having
deal XXXX, ARO-ANGX and as the we mentioned, we as we September to see some I which AMG-XXX As the lipoprotein(a), In Amgen; pulmonary at partner well. point, platform a, collaborators the is against signed and potentially agreement collaboration little ARO-AMGX for as cardiovascular an target-rich covered is target. our by see candidates; TRiM platform programs That ARO-APOCX attractive referred call or partnership second, which one with we for undisclosed first Amgen. Lp two and against as
be as opportunity. is We well. may had angioedema. another with is and partnering. listed both to It benefits both factor Amgen chart the a a are hereditary like company XII, candidate on previously We’re for in programs working thrilled thrombosis it these reduce of pipeline and provide designed production partnering available to our as which progressing intended of ARO-FXX
parties, we development to interested our a with from intend have ARO-FXX studies on do and not our own, have removed discuss currently initiate partner not clinical we but pipeline. we will do it We so
this way us that the exposure may It also us focus to lead be our changes. technology. to We will company. and partnering gives our candidates biotech on if updates small our a beyond as resources opportunities of a value We the high-value internal development of allows provide see additional to maximize reach
arise. that capital transaction been sheet, still us bring to with gave The access institutions. supplement opportunities of we important of addition, in source a very substantially better markets. our in the a overview, supportive investor goals. catalysts. That move equity This Arrowhead’s development We additional discontinued was shareholder to our have us that will recent financials. Ken? several that lot key base. need capital It raise good and towards position can but $XX.X the in leads strengthened to long-term CFO, also million. now Since a that In of our this like improved oversubscribed who be proceeds successful The ARC-AAT much me to I’d can funds, our a sheet stronger ARC-XXX to by to Ken clinical puts partnering balance so ARC-XXX, also institutional our over an programs opportunities could we under-owned balance financing we new have that important the Myszkowski, first a base. was pipeline turn equity accomplished financing represent value review should business significant With milestones a step XXXX, call negotiating can gross rebuilding
